GleamWall
中文EN

OMER OMEROS CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 1285819 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY181.2%
TTM EPS YoY176.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR70.1%

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA45.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets136.3%
Debt / equity—
Current ratio2.27x
Interest coverage-1.47x

Cash quality & payout

Operating cash flow / net income-0.38x
Accruals ratio62.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$81.30M$119.52M
SG&A expense$41.50M$47.43M
Operating income-$122.80M-$166.95M
Interest expense-$960,000$24.68M
Pretax income-$2.80M-$180.32M
Income tax$2.01M$2.31M
Net income-$3.35M-$156.81M
EBITDA-$121.83M-$166.00M
EPS (basic)-0.05-2.70
EPS (diluted)-0.05-2.70
Balance sheet
Cash & equivalents$9.66M$3.40M
Short-term investments$162.14M$86.73M
Receivables$0$7.74M
Inventory$0—
Current assets$215.67M$134.12M
PP&E, net$1.77M$2.68M
Total assets$325.63M$277.08M
Current liabilities$78.06M$79.53M
Long-term debt$51.36M$164.90M
Total debt$51.36M$164.90M
Total liabilities$446.86M$459.69M
Shareholders' equity-$121.23M-$182.61M
Net debt$41.70M$161.50M
Shares outstanding71.67M58.04M
Cash flow statement
Operating cash flow-$116.09M-$148.80M
Capital expenditure$65,000$165,000
Free cash flow-$116.16M-$148.97M
Investing cash flow$164.52M$82.22M
Financing cash flow-$42.17M$62.88M
Depreciation & amortization$964,000$950,000
Stock-based compensation$8.19M$10.49M
Share buybacks$0$11.85M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.